Insulet (US:PODD) ZACKS·2026-02-18 14:15分组1 - Insulet reported quarterly earnings of $1.55 per share, exceeding the Zacks Consensus Estimate of $1.48 per share, and showing an increase from $1.15 per share a year ago, resulting in an earnings surprise of +4.87% [1] - The company achieved revenues of $783.8 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.15%, and up from $597.5 million in the same quarter last year [2] - Insulet has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - Despite the positive earnings report, Insulet shares have declined approximately 13.3% since the beginning of the year, contrasting with the S&P 500's zero return [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is $1.20 on revenues of $703.22 million, and for the current fiscal year, it is $6.09 on revenues of $3.22 billion [7] 分组3 - The Medical - Products industry, to which Insulet belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, suggesting potential challenges for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for Insulet was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6]